586 related articles for article (PubMed ID: 33059626)
21. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
22. Early Acid Suppression Therapy Exposure and Fracture in Young Children.
Malchodi L; Wagner K; Susi A; Gorman G; Hisle-Gorman E
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31175146
[TBL] [Abstract][Full Text] [Related]
23. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia.
Park SK; Nam JH; Lee H; Chung H; Lee EK; Shin JY
J Gastroenterol Hepatol; 2019 Dec; 34(12):2135-2143. PubMed ID: 31145825
[TBL] [Abstract][Full Text] [Related]
24. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitor use and the risk of fractures among an older adult cohort.
Harding BN; Weiss NS; Walker RL; Larson EB; Dublin S
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):596-603. PubMed ID: 29493043
[TBL] [Abstract][Full Text] [Related]
26. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.
Hershcovici T; Fass R
Drugs; 2011 Dec; 71(18):2381-9. PubMed ID: 22117130
[TBL] [Abstract][Full Text] [Related]
27. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
28. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
Hu FL; Jia JC; Li YL; Yang GB
J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
[TBL] [Abstract][Full Text] [Related]
29. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.
Eom CS; Park SM; Myung SK; Yun JM; Ahn JS
Ann Fam Med; 2011; 9(3):257-67. PubMed ID: 21555754
[TBL] [Abstract][Full Text] [Related]
30. A multicenter cohort analysis of fractures in histamine-2-receptor antagonist treated pediatric patients.
Fleishman NR; Richardson T; Attard TM
Curr Med Res Opin; 2022 Apr; 38(4):565-570. PubMed ID: 35112645
[TBL] [Abstract][Full Text] [Related]
31. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
[TBL] [Abstract][Full Text] [Related]
32. Fracture risk of young adults receiving proton-pump inhibitors and H2-receptor antagonists.
Fedida B; Schermann H; Ankory R; Rotman D; Shichman I; Yoffe V; Shlaifer A; Luger E
Int J Clin Pract; 2019 May; 73(5):e13339. PubMed ID: 30829427
[TBL] [Abstract][Full Text] [Related]
33. Drugs for peptic ulcer disease and GERD.
Treat Guidel Med Lett; 2011 Sep; 9(109):55-60; quiz 2 p following 60. PubMed ID: 21860368
[No Abstract] [Full Text] [Related]
34. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
35. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
36. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus.
El-Serag HB; Wieman M; Richardson P
Aliment Pharmacol Ther; 2008 Jun; 27(12):1293-9. PubMed ID: 18363892
[TBL] [Abstract][Full Text] [Related]
37. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
[TBL] [Abstract][Full Text] [Related]
38. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).
Pohle T; Domschke W
Langenbecks Arch Surg; 2000 Aug; 385(5):317-23. PubMed ID: 11026702
[TBL] [Abstract][Full Text] [Related]
39. Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population-based nested case-control study.
Kumar S; Drake MT; Schleck CD; Johnson ML; Alexander JA; Katzka DA; Iyer PG
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1094-1102. PubMed ID: 28980336
[TBL] [Abstract][Full Text] [Related]
40. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy.
Rackoff A; Agrawal A; Hila A; Mainie I; Tutuian R; Castell DO
Dis Esophagus; 2005; 18(6):370-3. PubMed ID: 16336606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
